NCT02813408View on ClinicalTrials.gov

A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants

CompletedOBSERVATIONAL

Enrollment

226

Participants

Timeline

Start Date

May 3, 2016

Primary Completion Date

March 21, 2018

Study Completion Date

March 21, 2018

Conditions

Prostatic Neoplasms

Trial Locations (26)

Unknown

Holstebro

Næstved

Odense

Besançon

Beuvry

Bordeaux

Challes-les-Eaux

Chalon-sur-Saône

Dijon

Lyon

Marseille

Paris

Quimper

Saint-Mandé

Strasbourg

Toulouse

Berkshire

Birmingham

Bolton

Derby

Glasgow

Lancaster

Middlesbrough

Oldham

Sutton

Wolverhampton

All Listed Sponsors

lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT02813408 - A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants | Biotech Hunter | Biotech Hunter